Want to see BMRA full AI Analyst Report?
BMRA Stock Chart & Stats
$2.10
$0.04(2.21%)
At close: 4:00 PM EDT
$2.10
$0.04(2.21%)
Day’s Range― - ―
52-Week Range$1.45 - $3.21
Previous Close$1.6
Volume3.01K
Average Volume (3M)127.97K
Market Cap
$10.60M
Enterprise Value$8.41
Total Cash (Recent Filing)$1.34M
Total Debt (Recent Filing)$193.00K
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Oct 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding4,588,968
10 Day Avg. Volume371,083
30 Day Avg. Volume127,970
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.62
Price to Sales (P/S)1.54
P/FCF Ratio-2.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Fresh Funding And Insider AlignmentThe financing adds capital for operations and balance-sheet support while participation by the CEO and directors aligns leadership with new investors. The absence of warrants limits immediate security complexity, although the funds remain important for sustaining the business.
Strategic OptionalityA dedicated adviser broadens Biomerica’s ability to assess strategic transactions beyond standalone execution. Potential combinations or partnerships could improve scale, product reach, or resources, creating a route to strengthen the business if an attractive opportunity is identified.
Losses And Cash Burn Have NarrowedThe improvement in cash burn and narrower losses indicates some progress in controlling the financial deficit, even though cash flow remains negative. If sustained, this trend could extend the company’s funding runway and provide a better base for rebuilding operating performance.
Bears Say
Sharp Revenue Contraction And VolatilityRevenue remains far below earlier levels and has been volatile, limiting the scale available to absorb operating costs. A smaller and inconsistent sales base makes recurring investment harder to support and reduces confidence that the company can achieve sustainable operating leverage.
Low Margins And Persistent LossesVery low gross margins leave limited contribution from each product sale, while the deeply negative net margin shows that current revenue does not cover the company’s cost base. This combination weakens the durability of earnings and leaves little evidence of a sustainable path to profitability.
Persistent Cash Burn And Weakening Capital StructureOngoing cash outflows require external funding and reduce financial flexibility. At the same time, higher leverage and materially lower equity increase balance-sheet pressure, making future operations more dependent on financing while leaving less cushion if performance does not improve.
Biomerica News
BMRA FAQ
What was Biomerica Inc’s price range in the past 12 months?
Biomerica Inc lowest stock price was $1.45 and its highest was $3.21 in the past 12 months.
What is Biomerica Inc’s market cap?
Biomerica Inc’s market cap is $10.60M.
When is Biomerica Inc’s upcoming earnings report date?
Biomerica Inc’s upcoming earnings report date is Oct 09, 2026 which is in 32 days.
How were Biomerica Inc’s earnings last quarter?
Biomerica Inc released its earnings results on Sep 01, 2026. The company reported -$0.373 earnings per share for the quarter.
Is Biomerica Inc overvalued?
According to Wall Street analysts Biomerica Inc’s price is currently Overvalued.
Does Biomerica Inc pay dividends?
Biomerica Inc does not currently pay dividends.
What is Biomerica Inc’s EPS estimate?
Biomerica Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomerica Inc have?
Biomerica Inc has 4,588,968 shares outstanding.
What happened to Biomerica Inc’s price movement after its last earnings report?
Biomerica Inc reported an EPS of -$0.373 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biomerica Inc?
Currently, no hedge funds are holding shares in BMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biomerica Inc
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Technical Analysis
Strata Skin Sciences
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
―
Ownership Overview
11.03% Insiders
4.49% Mutual Funds
<0.01% Other Institutional Investors
84.16% Public Companies and
Individual Investors